Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Serplulimab + Chemotherapy in Advanced Solid Tumors with NED
NCT06531291Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer (PC), sponsored by Renji Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
surufatinibserplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)biliary tract cancer (BTC)gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06531291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531291.